Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 224, Issue 5, Pages 764-770Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiab300
Keywords
antibody avidity; COVID-19; neutralization assay; SARS-CoV-2; urea
Categories
Funding
- Land of Tyrol Doctoral Programme of Excellence HOROS, Fonds zur Forderung der wissenschaftlichen Forschung (FWF), Vienna, Austria [ZFW12530]
- Marie Sklodowska Curie Action project CORVOS, European Union [EU-H2020-MSCA-ITN-2019, 860064]
- FWF Austrian Science Fund Lise Meitner Award [M-3069-B]
Ask authors/readers for more resources
Research on IgG avidity maturation during SARS-CoV-2 infection showed an increase in avidity even in older individuals. High avidity was associated with residual neutralization capacity, especially in older age groups, highlighting the potential role of avidity assays as a cost-effective alternative for assessing immune system maturation and protection against further infections.
The kinetics of immunoglobulin G (IgG) avidity maturation during severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection obtained from 217 participants of the Ischgl cohort, Austria, was studied 0.5-1.5 months (baseline) and 7-8 months (follow-up) after infection. Me IgG avidity assay, using a modified IgG enzyme-linked immunosorbent assay (ELISA) and 5.5 M urea, revealed that old age does not diminish the increase in avidity, detected in all participants positive at both time points, from 18% to 42%. High avidity was associated with a marked residual neutralization capacity in 97.2.% of participants (211/217), which was even higher in the older age group, revealing an important role of avidity assays as easy and cheap surrogate tests for assessing the maturation of the immune system conveying potential protection against further SARS-CoV-2 infections without necessitating expensive and laborious neutralization assays.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available